Literature DB >> 20940329

Interference of monoclonal antibody therapies with serum protein electrophoresis tests.

Christopher R McCudden, Peter M Voorhees, Shirley A Hainsworth, Herbert C Whinna, John F Chapman, Catherine A Hammett-Stabler, Monte S Willis.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20940329     DOI： 10.1373/clinchem.2010.152116

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  18 in total

1.  Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

Authors:  Paul G Richardson; Sundar Jagannath; Philippe Moreau; Andrzej J Jakubowiak; Marc S Raab; Thierry Facon; Ravi Vij; Darrell White; Donna E Reece; Lotfi Benboubker; Jeffrey Zonder; L Claire Tsao; Kenneth C Anderson; Eric Bleickardt; Anil K Singhal; Sagar Lonial
Journal:  Lancet Haematol       Date:  2015-11-16       Impact factor: 18.959

Review 2.  An update on the role of daratumumab in the treatment of multiple myeloma.

Authors:  Caitlin Costello
Journal:  Ther Adv Hematol       Date:  2016-11-24

3.  Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.

Authors:  Katie L Thoren; Matthew J Pianko; Youssef Maakaroun; C Ola Landgren; Lakshmi V Ramanathan
Journal:  J Appl Lab Med       Date:  2018-05-31

4.  Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.

Authors:  Shinsuke Iida; Hirokazu Nagai; Gen Kinoshita; Masafumi Miyoshi; Michael Robbins; Dimple Pandya; Eric Bleickardt; Takaaki Chou
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

5.  MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.

Authors:  Lauren M Moore; Sun Cho; Katie L Thoren
Journal:  Clin Chim Acta       Date:  2019-02-18       Impact factor: 3.786

6.  Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

Authors:  Kazunori Murata; Samuel I McCash; Brittany Carroll; Alexander M Lesokhin; Hani Hassoun; Nikoletta Lendvai; Neha S Korde; Sham Mailankody; Heather J Landau; Guenther Koehne; David J Chung; Sergio A Giralt; Lakshmi V Ramanathan; Ola Landgren
Journal:  Clin Biochem       Date:  2016-09-21       Impact factor: 3.281

7.  Cinderella in Serum Protein Electrophoresis.

Authors:  Srinivas Narasimhachar Chakravarthy; Satish Ramanathan; Smitha Menon; Vijayakumar Valappil; Mathivanan Durairaj; Jayarani Arokia
Journal:  Indian J Clin Biochem       Date:  2017-03-10

Review 8.  Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Authors:  Philippe Moreau; Niels W C J van de Donk; Jesus San Miguel; Henk Lokhorst; Hareth Nahi; Dina Ben-Yehuda; Michele Cavo; Gordon Cook; Michel Delforge; Hermann Einsele; Sonja Zweegman; Heinz Ludwig; Christoph Driessen; Antonio Palumbo; Thierry Facon; Torben Plesner; Meletios Dimopoulos; Pia Sondergeld; Pieter Sonneveld; María-Victoria Mateos
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 9.  Minimal residual disease analysis in myeloma - when, why and where.

Authors:  Uday Yanamandra; Shaji K Kumar
Journal:  Leuk Lymphoma       Date:  2017-10-11

10.  A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis.

Authors:  Li Liu; Michael R Shurin; Sarah E Wheeler
Journal:  Clin Biochem       Date:  2019-11-11       Impact factor: 3.281
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.